Podcasts Health & Fitness Medicine NEJM Interviews NEJM Interview: Dr. Kevin Schulman on the recent approval of two PCSK9 inhibitors and what their prices could mean for insurance premiums.

NEJM Interview: Dr. Kevin Schulman on the recent approval of two PCSK9 inhibitors and what their prices could mean for insurance premiums.

Published: Oct. 21, 2015, 4:01 p.m.

b'Dr. Kevin Schulman is a professor of medicine and of business administration at Duke University. Stephen Morrissey, the interviewer, is the Managing Editor of the Journal. K.A. Schulman, S. Balu, and S.D. Reed. Specialty Pharmaceuticals for Hyperlipidemia - Impact on Insurance Premiums. N Engl J Med 2015;373:1591-3. B.M. Everett, R.J. Smith, and W.R. Hiatt. Reducing LDL with PCSK9 Inhibitors - The Clinical Benefit of Lipid Drugs. N Engl J Med 2015;373:1588-91.'